Parallel Advisors’s Lexeo Therapeutics LXEO Stock Holding History

Parallel Advisors’s Portfolio LXEO Stock Details LXEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2.11K	Buy	+625	New	+$2.83K	﹤0.01%	3628

Other funds holding LXEO

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

Privium Fund Management Amsterdam, Netherlands $516M AUM 18.66% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return

Soltis Investment Advisors St. George, Utah $2.19B AUM 21.45% 1-Year Est. Return

China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return

Abel Hall LLC Baton Rouge, Louisiana $556M AUM 43.18% 1-Year Est. Return

Parallel Advisors's LXEO Position: Q3 2026 in Review

Parallel Advisors opened a new position in Lexeo Therapeutics (LXEO) in Q3 2026: 625 shares worth $2.11K. The stake represents ﹤0.01% of the portfolio and ranks #3628 among its holdings.

31 funds tracked by Wall St. Rank hold LXEO as of Q3 2026.

Parallel Advisors held 625 shares of Lexeo Therapeutics worth $2.11K as of Q3 2026.
Lexeo Therapeutics was a new Parallel Advisors position in Q3 2026.
Lexeo Therapeutics made up ﹤0.01% of Parallel Advisors's portfolio in Q3 2026, its #3628 holding.
31 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q3 2026.

Based on Parallel Advisors's 13F filing for Q3 2026, filed 3 Nov 2026.